2018 | 2017 | 2016 | 2015 | 2014
DateTitle 
11/30/15Chiasma Announces Addition of James R. Tobin and John F. Thero to Board of Directors
Independent New Directors Bring a Wealth of Commercial, Operational and Financial Leadership Experience Within the Life Sciences Sector NEWTON, Mass., Nov. 30, 2015 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a late-stage biopharmaceutical company developing Mycapssa™ (octreotide capsules), an investigational oral drug for the maintenance therapy of adult patients with the orphan disease acromegaly, today announced that James R. Tobin and John F. Thero have joined the company's Board of Di... 
Printer Friendly Version
11/12/15Chiasma Reports Third Quarter 2015 Financial Results and Recent Business Highlights
– Builds out infrastructure in advance of April 15, 2016 PDUFA target date – – EMA accepts Phase 3 trial design – – Conference call scheduled for 5 p.m. ET today – NEWTON, Mass., Nov. 12, 2015 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a late-stage biopharmaceutical company developing Mycapssa™ (octreotide capsules), an investigational oral drug for the maintenance therapy of adult patients with the orphan disease acromegaly, today provided a corporate update and reported finan... 
Printer Friendly Version
11/11/15Chiasma to Present at Upcoming Investor Conferences
Presentations to be webcast at 4:30 p.m. ET on November 18 and 8:00 a.m. ET on December 8 NEWTON, Mass., Nov. 11, 2015 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a late-stage biopharmaceutical company developing Mycapssa™ (octreotide capsules), an investigational oral drug for the maintenance therapy of adult patients with the orphan disease acromegaly, today announced that management will provide an overview of the company during two upcoming investor conference presentations: St... 
Printer Friendly Version
10/30/15Chiasma Supports Acromegaly Awareness with Launch of New Online Resource for Patients and Caregivers
-- November 1 is Acromegaly Awareness Day -- NEWTON, Mass., Oct. 30, 2015 /PRNewswire/ -- Chiasma, Inc. (Nasdaq: CHMA), a late-stage biopharmaceutical company, today unveiled a new online resource to support people with the rare pituitary disorder acromegaly. This announcement coincides with Acromegaly Awareness Day on November 1, 2015. Experience the interactive Multimedia News Release here: http://www.multivu.com/players/English/7664751-chiasma-acromegaly-awareness-day-2015/ ... 
Printer Friendly Version
10/29/15Chiasma to Report Third Quarter 2015 Financial Results on November 12
-- Company to Host Conference Call at 5 p.m. ET -- NEWTON, Mass., Oct. 29, 2015 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a late-stage biopharmaceutical company developing Mycapssa™ (octreotide capsules), an investigational oral drug for the maintenance therapy of adult patients with acromegaly, today announced that it will be issuing its third quarter 2015 financial results after the market's close on Thursday, November 12, 2015. At 5:00 p.m. Eastern Time that day, Chiasma's senior ... 
Printer Friendly Version
08/31/15Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights
- Successfully completed initial public offering, raising $117.1M in gross proceeds - - New Drug Application for octreotide capsules in acromegaly accepted for filing by the FDA, with PDUFA date of April 15, 2016 - - Expands management team with appointment of Anand Varadan as Chief Commercial Officer - NEWTON, Mass. and JERUSALEM, Israel, Aug. 31, 2015 /PRNewswire/ -- Chiasma, Inc. (NASDAQ: CHMA), a U.S. late-stage biopharmaceutical company developing octreotide capsules for the orph... 
Printer Friendly Version
08/24/15Chiasma Appoints William H. Ludlam, M.D., Ph.D., as Vice President of Medical Affairs
- Well-known pituitary expert to provide senior medical and technical leadership for Company's planned commercial launch of octreotide capsules (Mycapssa™) - NEWTON, Mass. and JERUSALEM, Israel, Aug. 24, 2015 /PRNewswire/ -- Chiasma, Inc. (NASDAQ: CHMA), a U.S. late-stage biopharmaceutical company developing Mycapssa™ (octreotide capsules) for the maintenance therapy of adult patients with acromegaly, today announced the appointment of William H. Ludlam, M.D., Ph.D., as vice president of me... 
Printer Friendly Version
08/17/15Chiasma Announces FDA Acceptance For Filing of New Drug Application for Octreotide Capsules in Acromegaly
- Brand name of Mycapssa™ also conditionally accepted by agency - NEWTON, Mass. and JERUSALEM, Israel, Aug. 17, 2015 /PRNewswire/ -- Chiasma, Inc. (Nasdaq: CHMA), a U.S. late-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's New Drug Application (NDA) for the marketing and sale of octreotide capsules, an oral drug proposed for the maintenance therapy of adult patients with acromegaly. The FDA is expected t... 
Printer Friendly Version
08/10/15Chiasma Expands Management Team with Announcement of Anand Varadan as Chief Commercial Officer
- Experienced global commercialization executive to lead Company's launch strategy for oral octreotide capsules - NEWTON, Mass. and JERUSALEM, Israel, Aug. 10, 2015 /PRNewswire/ -- Chiasma, Inc., a U.S. late-stage biopharmaceutical company developing octreotide capsules for the orpha n condition acromegaly, today announced the appointment of Anand Varadan as chief commercial officer, effective August 17, 2015. Mr. Varadan brings more than 20 years of commercial experience to Chiasma and wil... 
Printer Friendly Version
07/21/15Chiasma, Inc. Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
NEWTON, Mass. and JERUSALEM, Israel, July 21, 2015 /PRNewswire/ -- Chiasma, Inc. ("Chiasma") today announced the closing of its initial public offering of 7,319,750 shares of common stock at a price of $16.00 per share, before underwriting discounts, which includes the exercise in full by the underwr iters of their option to purchase up to 954,750 additional shares of common stock. All of the common stock was offered by Chiasma. Chiasma's stock is listed on The NASDAQ Global Select Market under ... 
Printer Friendly Version
07/15/15Chiasma, Inc. Prices Initial Public Offering of Common Stock
NEWTON, Mass. and JERUSALEM, Israel, July 15, 2015 /PRNewswire/ -- Chiasma, Inc. ("Chiasma") today announced the pricing of its initial public offering of 6,365,000 shares of common stock at a price of $16.00 per share, before underwriting discounts. All of the common stock is being offered by Chiasma. In addition, Chiasma has granted the underwriters a 30-day option to purchase up to 954,750 additional shares of common stock at the public offering price, before underwriting discounts. Chia... 
Printer Friendly Version
06/15/15Chiasma Submits New Drug Application to U.S. FDA for Octreotide Capsules in Acromegaly
Submission based on positive results from Phase 3 clinical trialNewton, Mass. and Jerusalem, Israel, June 15, 2015 – Chiasma, Inc., a U.S. privately held biopharma company, today announced the company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the marketing and sale of octreotide capsules, an investigational drug for the maintenance treatment of adults with acromegaly. The FDA has a 60-day filing review period to determine wheth... 
Printer Friendly Version
05/18/15Chiasma Strengthens Management Team with Announcement of Chief Financial Officer
Biotechnology Industry Veteran Mark J. Fitzpatrick to Join Chiasma Newton, Mass. and Jerusalem, Israel, May 18, 2015 – Chiasma, Inc., a U.S. privately held biopharma company developing octreotide capsules for the orphan condition acromegaly, today announced the appointment of Mark J. Fitzpatrick as the company’s chief financial officer, by June 10, 2015.“Bringing on Mark as CFO will bolster our leadership team at a critical time in Chiasma’s corporate evolution,” said Mark Leuchtenberger, ch... 
Printer Friendly Version
05/11/15Chiasma Announces New Data for Investigational Octreotide Capsules to be Presented at ECE 2015
Studies show acromegaly patients face significant burdens with available treatment options Newton, Mass. and Jerusalem, Israel, May 11, 2015 – Chiasma, Inc., a U.S. privately held biopharma company developing octreotide capsules for the orphan condition acromegaly, today announced that two abstracts evaluating patients with acromegaly will be presented at the 17th European Congress of Endocrinology (ECE), being held in Dublin, Ireland, from May 16-20, 2015.“The data presented at this meeting add... 
Printer Friendly Version
03/16/15Chiasma Announces Mark Leuchtenberger as Chief Executive Officer
Proven Business Leader to Oversee Commercialization of Octreotide Capsules Newton, Mass. and Jerusalem, Israel, March 16, 2015 – Chiasma, Inc., a U.S. privately-held biopharma company developing octreotide capsules, its lead product for the orphan condition acromegaly, today announced the appointment of Mark Leuchtenberger as president and chief executive officer, effective immediately.Leuchtenberger brings 25 years of industry experience to Chiasma, including CEO positions with Acusphere, Rib-X... 
Printer Friendly Version
03/05/15Chiasma Announces New Data for Investigational Octreotide Capsules
Two studies presented at ENDO 2015 contribute to growing body of knowledge about acromegaly treatmentNewton, Mass. and Jerusalem, Israel, March 5, 2015 – Chiasma, Inc., a U.S. privately-held biopharma company developing octreotide capsules for the orphan condition acromegaly, today announced two new studies presented at the 97th Endocrine Society (ENDO) Annual Meeting in San Diego, Calif. The studies provide additional data from Chiasma’s Phase III trial and new findings on the patient burden of... 
Printer Friendly Version
02/27/15Chiasma Announces Completion of $70 Million Series E Financing
Newton, Mass. and Jerusalem, Israel, February 27, 2015 – Chiasma, Inc., a U.S. privately-held biopharma company developing octreotide capsules, its lead product for the orphan condition acromegaly, today announced the closing of a $70 million Series E financing round. Participants in the financing included new investors Rock Springs Capital and Sofinnova Ventures, and an undisclosed blue chip public investment fund, as well as existing investors MPM Capital, F2 Capital, 7 Med Health Ventures, Ab... 
Printer Friendly Version
02/23/15Chiasma Appoints David Stack as Chairman of the Board; John A. Scarlett, M.D. Joins Board of Directors
Newton, Mass. and Jerusalem, Israel, February 23, 2015 – Chiasma, Inc., a U.S. privately held biopharma company developing octreotide capsules, their lead product for the orphan condition acromegaly, today announced the appointment of David Stack, president, CEO and chairman of Pacira Pharmaceuticals, as chairman of the board and John “Chip” Scarlett, M.D., president and CEO of Geron Corporation, as a member of the board. “Chiasma will benefit from the deep experience and knowl... 
Printer Friendly Version
02/09/15Newly Published Phase III Study Results Show Positive Outcomes for Octreotide Capsules in People with Acromegaly
Data showed maintenance of disease control with an investigational oral form of octreotide New York, USA and Jerusalem, Israel, February 9, 2015 – Chiasma Inc., a U.S. privately-held biopharma company, announced today that results from a multicenter Phase III study of the investigational new drug, octreotide capsules, were published online for early release on Feb. 9, ahead of print, by the Journal of Clinical Endocrinology & Metabolism (JCEM). The investigational drug, octreotide caps... 
Printer Friendly Version

This section of our website may contain dated or archived information which should not be considered current and may no longer be accurate. For current information, you are encouraged to review our most recent filings with the U.S. Securities and Exchange Commission.